Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Videos|March 10, 2022
Migraine Management Pearls for Primary Care with Neurologist Jessica Ailani, MD
Author(s)Grace Halsey
Consider migraine screening for all women aged 20 to 50 years, suggests Ailani; you'll likely find a majority of them have migraine. More pearls follow.
Advertisement
Consider migraine screening in primary care for all women aged 20 to 50 years because “you’re probably going to find that a majority of them have migraine.”
Take advantage of simple online tools to help quickly assess for migraine headache in a busy clinical practice.
Once it is diagnosed, make sure a patient with migraine understands that migraine is not just a symptom, it is a disease that will need long-term management.
These are just a few of the suggestions about migraine management offered to primary care clinicians by headache specialist Jessica Ailani, MD, during a recent interview with Patient Care® Online. She explains these and offers other ideas and clinical pearls in this short video.
Jessica Ailani, MD, is professor of clinical neurology and director of Medstar Georgetown Headache Center at the MedStar Georgetown University Hospital in Washington, DC.
Advertisement
Related to this article
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.
The FDA granted Breakthrough Device designation to Natera's cell-free DNA multi-cancer early detection assay. What it means for primary care.
Most adolescents with sporadic colorectal cancer present with stage III or IV disease, and few have a family history, per data presented at AAP 2026.
Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood screening test.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Grants Breakthrough Device Designation to Natera's Multi-Cancer Early Detection Blood Test
2
Most Adolescents With Colorectal Cancer Diagnosed at Advanced Stage, Study Finds
3
Building Clinician Confidence to Prescribe HIV PrEP in Primary Care
4
PrEP Deserts: Why HIV Prevention Still Misses Those at Risk
5